PULSE the living trend engine
🤖 Open Intelligence Dossier available for AI agents & citation View Markdown (.md) →
◼ Archived Health

New outbreak of mpox in Anchorage prompts advisory from state health officials

Alaska health officials report four new mpox cases in Anchorage with no recent travel history, the state's highest annual count since 2022 and the first confirmed clade Ib infections in Alaska.

7sources
8articles
5velocity
+165%since first seen
8d agofirst detected

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

The brief

Alaska health officials have confirmed four new mpox cases in Anchorage, marking the state's highest annual total since 2022 when five cases were diagnosed during a global outbreak. Between 2023 and 2025, Alaska recorded only two cases. None of the four patients reported traveling outside Alaska in the 30 days before becoming infected, a contrast with all previous Alaska cases which involved recent travel, according to the Anchorage Daily News and JournalArta.

Three cases emerged in October and were reported last week through a state Department of Health alert. The fourth case was reported to state officials on Thursday, said Dr. Joe McLaughlin, Alaska's state epidemiologist. All four patients are men who are isolating and recovering. Two of the cases are among men who are partners, but it is unknown whether additional links exist among the patients, McLaughlin said.

The first two cases were caused by clade Ib mpox, marking the first reported cases of clade I mpox in Alaska; clade determination for the third case is pending, according to Outbreak News Today. The global outbreak that began in 2022 was caused by clade IIb. Since March 2026, imported cases of clade I mpox have increased, and presumed local transmission has been reported in 15 U.S. jurisdictions since August 2026. Historically, clade I has been associated with greater disease severity and higher case-fatality ratios than clade II, but recent clade I outbreaks have demonstrated substantially lower mortality, particularly when appropriate medical care is available.

Officials are currently trying to track the source of infection. Dr. Randi Rollins, a U.S. Centers for Disease Control epidemiologist working with the Alaska Department of Health, cautioned that the lack of reported out-of-state travel "does not necessarily establish that the monkeypox virus is circulating here in Alaska. They may have had exposure to somebody who traveled to Alaska, and they may be the end of that transmission line at this point. We don't know."

Symptoms usually appear three to 17 days after infection. The first phase resembles flu with fever, chills, fatigue, headache, sore muscles, and swollen lymph nodes. Lesions develop in the second phase as bumps that are firm or sometimes tender. Some people skip early symptoms and show signs only when the rash develops. The illness lasts a few weeks, and patients are considered recovered once all lesions are gone. Until the last lesion heals, "the person is still infectious and can transmit monkeypox, and that can typically take two to four weeks," Rollins said.

Alaska health officials are encouraging anyone at risk of infection to get vaccinated. The JYNNEOS vaccine, approved by the FDA in 2019, protects against both clades of mpox and smallpox. It is administered in two doses and available through the Anchorage Health Department and other providers. The vaccine is recommended for men who have sex with men, anyone with exposure to a person suspected of having mpox, people traveling to areas with mpox outbreaks, and medical workers at risk of exposure. State immunization records show that since 2022, 851 people in Alaska have received a first dose and 604 a second dose. For anyone exposed, vaccination within four days of exposure is recommended, though it can be effective up to about 14 days in reducing disease severity.

Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 7d ago.

Quick answers

How many mpox cases have been confirmed in Anchorage and what is significant about them?

Four mpox cases have been confirmed in Anchorage, the highest annual count in Alaska since 2022. None of the patients reported recent out-of-state travel, and the first two cases are Alaska's first confirmed clade Ib infections.

What is the difference between clade I and clade II mpox?

The 2022 global outbreak was caused by clade IIb. The current cases are clade I, which historically has been associated with greater disease severity and higher case-fatality ratios than clade II, but recent clade I outbreaks have shown substantially lower mortality with appropriate medical care.

What vaccine is available for mpox and who should get it?

The JYNNEOS vaccine, approved by the FDA in 2019, protects against both clades of mpox and smallpox. It is given in two doses and recommended for men who have sex with men, people exposed to someone with mpox, travelers to outbreak areas, and medical workers at risk of exposure.

Coverage (8)

Topics

Related trends

↑ Rising Health

The Virus That Makes Your Immune System Forget

Measles remains a highly contagious and potentially deadly disease, with an estimated 95,000 deaths in 2024, mostly children under five, despite a safe and inexpensive vaccine.

12 sources 12 articles v 10 2h ago
\n \n \n \n \n \n \n